This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Acute promyelocytic leukaemia: population-based study of epidemiology and outcome with ATRA and oral-ATO from 1991 to 2021
BMC Cancer Open Access 10 February 2023
-
Institutional factors associated with early mortality of newly diagnosed acute promyelocytic leukemia
Blood Cancer Journal Open Access 15 December 2022
-
All-trans retinoic acid 45 mg/m2 is superior to 25 mg/m2 as the first induction regimen for the treatment of acute promyelocytic leukaemia: a retrospective analysis in a real-world clinical setting
Blood Cancer Journal Open Access 29 January 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997; 337: 1021–1028.
Ades L, Chevret S, Raffoux E, de Botton S, Guerci A, Pigneux A et al. Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group. J Clin Oncol 2006; 24: 5703–5710.
Sanz MA, Montesinos P, Rayon C, Holowiecka A, de la Serna J, Milone G et al. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood 2010; 115: 5137–5146.
Lo Coco F, Avvisati G, Vignetti M, Fioritoni G, Liso V, Ferrara F et al. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation: results of the AIDA-2000 Trial of the Italian GIMEMA Group. blood 2004; 104: 392.
Montesinos P, Bergua JM, Vellenga E, Rayon C, Parody R, de la Serna J et al. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-transretinoic acid and anthracycline chemotherapy: characteristics, outcome and prognostic factors. Blood 2008; 113: 775–783.
De Botton S, Dombret H, Sanz M, Miguel JS, Caillot D, Zittoun R et al. Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 1998; 92: 2712–2718.
Park JH, Qiao B, Panageas KS, Schymura MJ, Jurcic JG, Rosenblat TL et al. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood 2011; 118: 1248–1254.
Lehmann S, Ravn A, Carlsson L, Antunovic P, Deneberg S, Mollgard L et al. Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry. Leukemia 2011; 25: 1128–1134.
McClellan JS, Kohrt HE, Coutre S, Gotlib JR, Majeti R, Alizadeh AA et al. Treatment advances have not improved the early death rate in acute promyelocytic leukemia. Haematologica 2012; 97: 133–136.
Altman JK, Rademaker A, Cull E, Weitner BB, Ofran Y, Rosenblat TL et al. Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death. Leuk Res 2013; 37: 1004–1009.
Kelaidi C, Chevret S, De Botton S, Raffoux E, Guerci A, Thomas X et al. Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience. J Clin Oncol 2009; 27: 2668–2676.
Paulson K, Serebrin A, Lambert P, Bergeron J, Seftel M et al. Acute promyelocytic leukaemia is characterized by stable incidence and improved survival that is restricted to patients managed in leukaemia referral centres: a pan-Canadian epidemiological study. Br J Haematol 2014; 166: 660–666.
Acknowledgements
Author contributions
XT, CR, NV, JD, ED, PH, DB, J-BM, AS, CM, CP, PB, J-PM, MH-B, NF, ER and HD provided the data. RR collected the data. LD, PF and LA designed the research. RR, PF and LA wrote the paper. LA analyzed the data.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Rahmé, R., Thomas, X., Recher, C. et al. Early death in acute promyelocytic leukemia (APL) in French centers: a multicenter study in 399 patients. Leukemia 28, 2422–2424 (2014). https://doi.org/10.1038/leu.2014.240
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2014.240
This article is cited by
-
Acute promyelocytic leukaemia: population-based study of epidemiology and outcome with ATRA and oral-ATO from 1991 to 2021
BMC Cancer (2023)
-
Institutional factors associated with early mortality of newly diagnosed acute promyelocytic leukemia
Blood Cancer Journal (2022)
-
Aktueller diagnostischer Standard und Risikostratifizierung der AML
InFo Hämatologie + Onkologie (2022)
-
All-trans retinoic acid 45 mg/m2 is superior to 25 mg/m2 as the first induction regimen for the treatment of acute promyelocytic leukaemia: a retrospective analysis in a real-world clinical setting
Blood Cancer Journal (2021)
-
Sequential Treatment of Arsenic Trioxide Followed by All Trans Retinoic Acid with Anthracyclines has Excellent Long-Term Cure in Acute Promyelocytic Leukemia
Indian Journal of Hematology and Blood Transfusion (2021)